E Fund (HK) Solactive Biopharma Select Index ETF

As of 31-08-2026

Important Notes: 1) E Fund (HK) Solactive Biopharma Select Index ETF (the "Sub-Fund") is a sub-fund of E Fund ETFs Trust, an umbrella unit trust established under Hong Kong law. The Sub-Fund is a passively-managed ETF falling within Chapter 8.6 of the Code on Unit Trusts and Mutual Funds issued by the Securities and Futures Commission (the "SFC"). Units of the Sub-Fund (the "Units") are traded on The Stock Exchange of Hong Kong Limited (the "SEHK") like stocks. The investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive Biopharma Select Index (the "Index"). 2) Investment involves risks. The Fund is subject to a) Investment risk, b) Equity market risk, c) New Index risk, d) Geographical concentration risk, e) Political, economic and social risks in mainland China, f) Biopharmaceuticals sector concentration risk, g) Risk associated with small-capitalisation / mid-capitalisation companies, h) Securities lending transactions risk, i) Trading differences risk, j) Passive investments risk, k) Trading risk, l) Tracking error risk, m) Currency risk, n) Distribution out of/effectively out of capital risk, o) Reliance on market maker risk, p) Termination risk. The value of the Sub-Fund can be volatile and may go down substantially. Investors may suffer losses. 3) The Sub-Fund may invest in derivatives for hedging or investment purposes to the extent permitted by the Code and in adverse situations its use of financial derivative instruments may become ineffective and/or cause the Sub-Fund to suffer significant loss. 4) Distributions of the Sub-Fund may be paid out of the capital of the Sub-Fund. Investors should note that payment of distributions out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment and such distributions will result in an immediate reduction of the net asset value of the relevant units. 5) The Sub-Fund is traded on the exchange at market price, which may be different from its net asset value. Offering documents of the Sub-Fund can be obtained from https://www.efunds.com.hk/products/ 6) The Index is a new index. The Index has minimal operating history by which investors can evaluate its previous performance. There can be no assurance as to the performance of the Index. The Sub-Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history. 7) As the Sub-Fund's investments are concentrated in securities of Biopharmaceuticals companies in Hong Kong and the United States, and those companies may significantly be impacted by technological changes, increased governmental regulations and intense competition from competitors, the Sub-Fund is subject to sector and geographical concentration risks and its Net Asset Value is therefore likely to be more volatile than a broad-based fund. 8) You should not invest in the Sub-Fund unless the intermediary who sells it to you has explained to you that the Sub-Fund is suitable for you having regard to your financial situation, investment experience and objectives. 9) Investors should not invest in the Sub-Fund based on this document alone. Before making any investment decision, the investor should read the Sub-Fund's offering documents carefully including the risk factors.

Fund Information

Fund Manager:	E Fund Management (Hong Kong) Co., Limited
Trading Board Lot Size:	100
Inception date:	2026-03-20
Listing Date:	2026-03-23
Base Currency:	HKD
Dealing & Valuation Frequency:	Daily
Index Bloomberg Ticker:	SOLG2BTN
Underlying Index:	Solactive Biopharma Select Index
Index Type:	Net Total Return
Trustee:	HSBC Institutional Trust Services (Asia) Limited
Auditor:	PricewaterhouseCoopers
Fund Size:	HKD 25.04 million
Legal Structure:	Unit Trust
Domicile:	Hong Kong

Investment Objective Summary

The investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive Biopharma Select Index.


Share Class Information

Trading Currency	NAV	ISIN Code	Bloomberg Ticker	HKEX Stock Code	Management Fee[1]
HKD Counter	14.7321	HK0001254553	3186 HK	3186	0.90%

Performance[2]

	1Month	3Months	6Months	1Year	YTD	Since Launch
Fund	-	-	-	-	-	-
Underlying Index	-	-	-	-	-	-

HKD Counter Historical NAV Per Unit Since Launch



Sector Exposure[3]



Geographical Exposure[4]



Source: E Fund HK and Bloomberg unless specified otherwise.

Notes: Past performance information is not indicative of future performance. Investors may not get back the full amount invested. Performance data has been calculated in the respective currencies of the classes, including ongoing charges and excluding subscription fee and redemption fee you might have to pay. No performance data can be displayed until 6 months from inception date. Where no past performance is shown there was insufficient data available in that year /period to provide performance.

1 You should note that some fees may be increased, up to a specified permitted maximum 3%, by giving Unitholders at least one month's prior notice. For details please refer to the related section in the Explanatory Memorandum/Prospectus.

2 NAV-to-NAV return, total return with dividend (if any) reinvested. For the performance of the class launch year, it reflects the period from the launch date to the year-end. As the class was not in operation for a full calendar year, it may not be indicative of long-term performance under varying market conditions.

3 Sector Exposure is expressed as a percentage of the aggregate market value of all holdings of time deposits, securities and derivatives (if any), where holdings such as collective investment schemes and derivatives (if any) are included in "Others".

4 Geographical Exposure refers to the listing location of securities and is expressed as a percentage of the aggregate market value of all holdings of time deposits, securities and derivatives (if any), where holdings such as collective investment schemes and derivatives (if any) are included in "Others".

Top 10 Holdings[1]

Top 10 Holdings	Stock Code	%
Keymed Biosciences Inc	2162 HK	3.28%
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	6990 HK	2.97%
Zai Lab Ltd	9688 HK	2.94%
Innovent Biologics Inc	1801 HK	2.87%
InnoCare Pharma Ltd	9969 HK	2.78%
BeOne Medicines Ltd	6160 HK	2.68%
Hansoh Pharmaceutical Group Co Ltd	3692 HK	2.42%
CSPC Pharmaceutical Group Ltd	1093 HK	2.30%
Simcere Pharmaceutical Group Ltd	2096 HK	2.19%
Remegen Co Ltd	9995 HK	2.15%

Market Makers:HKD Counter

Flow Traders Hong Kong Limited
Optiver Trading Hong Kong Limited

Participating Dealers

China Merchants Securities (HK) Co., Ltd
GF Securities (Hong Kong) Brokerage Limited
Haitong International Securities Company Limited
The Hongkong and Shanghai Banking Corporation Limited
UBS Securities Hong Kong Limited
Huatai Financial Holdings(Hong Kong) Limited
Mirae Asset Securities (HK) Limited

Source: E Fund HK and Bloomberg unless specified otherwise.

Notes: 1 Top 10 Holdings are the 10 largest holdings of time deposits, securities and derivatives (if any), expressed as a percentage of the aggregate market value of all holdings of time deposits, securities and derivatives (if any), plus cash and cash equivalent.

Disclaimer:E Fund Management (Hong Kong) Co., Limited is the issuer of this report. This report is neither an offer nor solicitation to purchase units of the fund; applications for units may only be made on forms of application available with the Explanatory Memorandum. Investments are subject to investment risks, fund value may go up as well as down and past performance is not indicative of future performance. Investors should read carefully the Explanatory Memorandum (including the section "Risk Factors") for the relevant risks associated with the investment in the fund before investing. Distribution of this report may be restricted in certain jurisdictions. This report does not constitute the distribution of any information or the making of any offer or solicitation by anyone in any jurisdiction in which such distribution or offer is not authorized or to any person to whom it is unlawful to distribute such a report or make such an offer or solicitation. This report is exempted from pre-vetting and authorization by the Securities and Futures Commission of Hong Kong and has not been reviewed by the Securities and Futures Commission of Hong Kong. SFC authorization is not a recommendation or endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. Copyright© 2026. E Fund Management (Hong Kong) Co., Limited. All rights reserved.
Index Provider Disclaimer: Solactive AG ("Solactive") is the licensor of Solactive Biopharma Select Index (the "Index"). The financial instruments that are based on the Index are not sponsored, endorsed, promoted or sold by Solactive in any way and Solactive makes no express or implied representation, guarantee or assurance with regard to: (a) the advisability in investing in the financial instruments; (b) the quality, accuracy and/or completeness of the Index; and/or (c) the results obtained or to be obtained by any person or entity from the use of the Index. Solactive does not guarantee the accuracy and/or the completeness of the Index and shall not have any liability for any errors or omissions with respect thereto. Notwithstanding Solactive's obligations to its licensees, Solactive reserves the right to change the methods of calculation or publication with respect to the Index and Solactive shall not be liable for any miscalculation of or any incorrect, delayed or interrupted publication with respect to the Index. Solactive shall not be liable for any damages, including, without limitation, any loss of profits or business, or any special, incidental, punitive, indirect or consequential damages suffered or incurred as a result of the use (or inability to use) of the Index.

E Fund Management (Hong Kong) Co., Limited
Address: 12/F, Nexxus Building, 41 Connaught Road Central, Hong Kong
For enquiries: (852) 3929 0960
Email: clientservice@efunds.com.hk
Website: www.efunds.com.hk